UPDATE 1-Dynavax hepatitis C drug shows promise in phase 1 trial

* Drug SD-101 was safe and showed anti-viral response

* All patients at highest dose saw reduction in viral load

* Shares soar 30 pct before the bell

Jan 26 (BestGrowthStock) – Dynavax Technologies Corp (DVAX.O: ) said
its experimental treatment for chronic hepatitis C infection
was safe and induced anti-viral activity in patients in an
early-stage trial, sending the company’s shares up 30 percent
in premarket trade.

The trial evaluated four dose levels of the drug, SD-101,
in 34 chronically infected, treatment-naive hepatitis C
patients, and showed all the patients at the highest dose
experienced a reduction in viral load, or the severity of the
viral infection. Dynavax also posted the results from an
in-vitro study of the drug’s mechanism of action in human blood
cells.

The study showed SD-101 stimulated much higher levels of
two certain types of interferons, or proteins that are released
by the body in response to the presence of viruses and
bacteria, compared to first-generation drugs of the same kind.

Shares of the company, which is also developing a vaccine
for hepatitis B infection, were up 30 percent to $1.94 in
trading before the bell. They closed at $1.49 Monday on
Nasdaq.

Stock Market News
(Reporting by Esha Dey in Bangalore; Editing by Aradhana
Aravindan)

UPDATE 1-Dynavax hepatitis C drug shows promise in phase 1 trial